Gordon McGregor

Research output per year

If you made any changes in Pure these will be visible here soon.

Filter

2016

MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours
Woodcock, V., Middleton, M., Rolfo, C., Elez, E., Van Schaeybroeck, S., Taieb, J., Houlden, J., Collins, L., Love, S., Roberts, C., Andre, T., Jones, R., Lawler, M., Di Nicolantonio, F., Grayson, M., Bardelli, A., Laurent=puig, P., McGregor, G., Maughan, T., Tabernero, J. & 2 others, Peeters, M. & Wilson, R., 11 Oct 2016, MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. National Cancer Research Institute
Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Search results